Zio AT ECG Monitoring System vs IM007
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Zio AT is ideal for continuous, long-term external ECG monitoring for arrhythmia detection using its proprietary wearable patch. In contrast, IM007 specializes in aggregating and analyzing data from various cardiac implantable electronic devices (CIEDs) to streamline management and reduce false alerts for patients already with such devices. While both leverage AI for remote cardiac monitoring, their distinct data acquisition methods and primary use cases make them complementary rather than direct substitutes.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The Zio AT ECG Monitoring System monitors ECG data through a wearable patch for continuous recording. In contrast, IM007 aggregates data from various cardiac implantable electronic devices (CIEDs) such as those from Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort.
Zio AT utilizes an FDA-cleared deep-learned AI algorithm (ZEUS System) primarily for detecting arrhythmias from continuous ECG recordings. IM007 employs AI for broader applications, including reducing false alerts from CIED data (e.g., ILR ECG Analyzer, AF alerts) and providing predictive analytics for heart failure hospitalization risk (SignalHF).
Zio AT focuses on continuous, uninterrupted ECG recording for up to 14 days to detect symptomatic and asymptomatic cardiac events. IM007 aims to streamline workflows, reduce false alerts, and improve patient outcomes in cardiology and heart failure management by aggregating and analyzing data from all CIEDs.
Zio AT provides comprehensive end-of-wear reports and a ZioSuite clinician portal for patient management and report interpretation. IM007 offers unified device data aggregation, smart workflow automation for billing, reporting, and scheduling, and EHR integration capabilities via a bidirectional API.
With Zio AT, patients wear a continuous ECG recording patch for up to 14 days and can use the MyZio patient mobile app for symptom logging. IM007 monitors data from existing cardiac implantable electronic devices and includes automated SMS for managing disconnected patients.
Zio AT focuses on the detection of symptomatic and asymptomatic cardiac events through continuous ECG monitoring. IM007 specifically offers SignalHF, an FDA-cleared predictive AI designed to assess heart failure hospitalization risk.
More Comparisons
Backers
Who funded each tool's parent company.